Abstract: Disclosed are a composition and a method for freeze-drying which allow excellent stability, safety, and efficacy to be exhibited at the time of freeze-drying and reconstituting a composition for anionic drug delivery.

Abstract: Disclosed is a method capable of selectively synthesizing cationic lipids by controlling the introduction rate of a fatty acid group with respect to an oligoalkyleneamine by the change of reaction conditions.

Abstract: The present invention relates to a polymer nanoparticle freeze-dried product, and a preparation method therefor, the polymer nanoparticle freeze-dried product being obtainable by treating, through a freeze-drying process comprising an annealing step, a polymer nanoparticle aqueous solution comprising an amphiphilic block copolymer, a polylactic acid derivative having a carboxyl terminal group, and a freeze-drying adjuvant, wherein the polymer nanoparticle freeze-dried product is reconstituted within five minutes upon reconstitution by means of an aqueous solvent under atmospheric pressure.

Abstract: The present invention relates to an emulsion composition for chemoembolization comprising a nanoparticle comprising a drug and a biocompatible polymer, a water-soluble contrast agent and a water-insoluble contrast agent, and a water-insoluble drug as well as an aqueous drug can be administered in a form of stable emulsion, and drugs are slowly released, thereby enhancing the effect of chemoembolization.

Abstract: Disclosed are an oral solid dosage form composition comprising an active ingredient and a solubilizing carrier wherein a foaming ingredient is used to improve disintegration, dispersion or dissolution, and a preparation method therefor.

Abstract: A method for analyzing related substances in a pharmaceutical composition containing an amphiphilic block copolymer comprising a hydrophilic block and a hydrophobic block as a polymeric drug carrier, related substances identified thereby, and a method for evaluating a pharmaceutical composition by using the same are provided. Preferably, the method comprises evaluating a polymeric micelle pharmaceutical composition, which comprises an amphiphilic block copolymer comprising a hydrophilic block (A) and a hydrophobic block (B), and paclitaxel or docetaxel as a poorly water-soluble drug, by using a compound represented by Chemical Formula 1, wherein the hydrophilic block (A) comprises one or more selected from the group consisting of polyethylene glycol or derivatives thereof, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylamide and combinations thereof; and the hydrophobic block (B) is polylactide.

Abstract: A pharmaceutical composition containing a specific related compound within a specified limit and a method for preparing the same are provided.

Abstract: The present invention relates to a sealant syringe assembly.

Abstract: Provided are: a method for preparing biodegradable polymer microparticles and, particularly, porous microparticles of a biodegradable polymer; and biodegradable polymer microparticles prepared thereby, particularly, porous microparticles of a biodegradable polymer.

Abstract: Disclosed are: a composition having improved water solubility and bioavailability, containing sorafenib and a polymethacrylate copolymer; and a preparation method therefor.

Abstract: The present invention relates to porous microparticles of a biodegradable polymer, and a polymer filler comprising the same.

Abstract: The present disclosure relates to an oral tablet composition comprising lenalidomide and a method for preparing the same. More particularly, the present disclosure relates to a tablet-type composition and a method for preparing the same wherein the composition exhibits physicochemical equivalence with lenalidomide preparations of hard capsules, has the same pharmacological, therapeutic effect in non-clinical studies and bioequivalence studies, and also has improved ease of taking, handling, safety and the like.

Abstract: Disclosed are a pharmaceutical composition containing plasmid DNA, characterized by that it comprises plasmid DNA as active ingredients; a peptide comprising a nuclear localization signal (NLS) sequence or RGD peptide sequence; a cationic compound; and an amphiphilic copolymer, and the plasmid DNA binds to a peptide to form a complex with the cationic compound and the complex is entrapped in the nanoparticle structure of the amphiphilic block copolymer, and a preparation method thereof.

Abstract: The present invention relates to an amphiphilic block copolymer composition which provides enhanced stability to a micelle formed by an amphiphilic block copolymer in an aqueous phase.

Abstract: Provided are a composition containing an unstable drug against oxidation like pemetrexed with improved stability and a preparation method thereof, by removing oxygen during the preparation. The method is readily applicable for manufacturing by freezing and degassing in a sealed chamber, and can provide formulations with significantly increased stability for the unstable drug against oxidation.

Abstract: The present disclosure relates to a process for obtaining an ultrapure polymer by simply and effectively removing unreacted residual monomer in polymer, which is generated during production of a biodegradable polymer such as polylactic acid or derivatives thereof.

Abstract: Disclosed is a method capable of selectively synthesizing cationic lipids by controlling the introduction rate of a fatty acid group with respect to an oligoalkyleneamine by the change of reaction conditions.

Abstract: Provided are a composition containing an unstable drug against oxidation like pemetrexed with improved stability and a preparation method thereof, by removing oxygen during the preparation without use of an antioxidant. The method is readily applicable for manufacturing by freezing and degassing in a sealed chamber, and can provide formulations with significantly increased stability for the unstable drug against oxidation.

Abstract: Disclosed are an anionic drug-containing polymeric micelle particle comprising: an anionic drug as an active ingredient; a cationic lipid; and an amphiphilic block copolymer, wherein the anionic drug forms a complex with the cationic lipid, and the complex is entrapped in the micelle structure of the amphiphilic block copolymer, and a method for preparing the same. The particle may increase stability of the anionic drug in blood or in a body fluid, and it may enable intracellular delivery to improve efficacy of anionic drugs.

Abstract: Disclosed is a mucoadhesive pharmaceutical composition comprising a poly-ionic complex of chitosan and a polyacrylic acid polymer. As an oral formulation, the composition has the extended retention time in the gastrointestinal tract by its mucoadhesive and swelling properties, which is useful as sustained release formulations, retentive formulations of active ingredients with limited absorption regions, and active ingredients with pH dependent solubility.